NCT00964210View on ClinicalTrials.gov

Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination

PHASE3CompletedINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2010

Study Completion Date

April 30, 2011

Conditions
Cervical Cancer
Interventions
DRUG

Licensed quadrivalent HPV vaccine, Gardasil

The dose of the four valent (4v) HPV vaccine is 0.5ml administered by intramuscular (IM)injection. The recommended schedule is 0, 2 and 6 months.

Trial Locations (1)

3152

Royal Childrens Hospital, Melbourne

Sponsors
All Listed Sponsors
collaborator

Brockhoff Foundation Australia

UNKNOWN

collaborator

Shepherd Foundation Australia

UNKNOWN

lead

Murdoch Childrens Research Institute

OTHER